FOLH1 and prostate cancer: Although several other prostate antigens, such as PSMA and PSCA, are being tested clinically with T cell–engaging bispecific antibodies, CAR-Ts, and antibody-drug conjugates, the field is currently learning about the suitability of these targets and the efficacy of these modalities in the prostate cancer setting.